Glenmark Pharmaceuticals Ltd (NSE:GLENMARK)
₹ 1194.15 -15.7 (-1.3%) Market Cap: 336.71 Bil Enterprise Value: 330.69 Bil PE Ratio: 0 PB Ratio: 4.40 GF Score: 83/100

Q3 2023 Glenmark Pharmaceuticals Ltd Earnings Call Transcript

Feb 13, 2023 / 04:00AM GMT
Release Date Price: ₹422.6 (+5.54%)
Operator

Good morning, ladies and gentlemen. Welcome to the Q3 FY '23 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you, and over to you, sir.

Utkarsh Gandhi

Thank you, moderator. Good morning, everyone, and a very warm welcome to the Q3 FY '23 results conference call of Glenmark Pharmaceuticals Limited. Before we start the call, a review of the operations for the company for quarter ended December 31, 2022. For the third quarter of FY '23, Glenmark's consolidated revenue from operations was at INR 34,639 million as against INR 31,734 million in the corresponding quarter last year, recording a growth of 9.2%. For 9 months of FY '23, Glenmark's consolidated revenue was at INR 96,164 million as against INR 92,858 million, recording a growth of 3.6% year-on-year.

We start with the formulation business and we'll start off with India. Sales from the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot